High single-digit value growth in H2 FY26
Management aims for high single-digit value growth in H2 FY26, driven by export demand and new capacities.
AARTIDRUGS / guidance tracker
Keep management guidance in view.
Aarti Drugs · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
15% EBITDA margin target by end of FY27
Targeting 15% EBITDA margin on a consolidated basis by H2 FY27, driven by ramp-up of new plants and cost efficiencies.
15-20% revenue growth aspiration for FY27
If salicylic acid ramp-up succeeds, management expects 15-20% revenue growth in FY27.
Capex of ₹150-200 crore in FY26
Total capex for FY26 estimated at ₹150-200 crore, with similar levels expected in FY27 for further expansions.
Volume growth of 12-15% in FY27
Management expects 12-15% volume growth in FY27, driven by new products (salicylic acid, methylamines) and single-digit growth in existing basket.
EBITDA margin recovery to 12-13% near-term, 14-15% steady-state
Management targets EBITDA margin of 12-13% in the near term and 14-15% at steady state, driven by backward integration, export mix, and formulation ramp-up.
Sikar plant utilization to reach 50% by March 2026, 75% next quarter
Sikar facility expected to ramp to 50% utilization in Q4 FY26 and 75% in the subsequent quarter, with full utilization within 12 months.
Capex of ₹150-200 crore per year for next two years
Management guided for annual capex of ₹150-200 crore over the next two years, including oncology product development, brownfield expansions, and energy improvements.
Methylamine plant utilization target 55-60% in Q1 FY27
Management expects to cross 55-60% utilization in the June quarter, with a path to >70% within a year.
Volume growth target of 8-10% for FY27
Management targets 8-10% volume growth, with internal aspirations of 10-15%, supported by new capacities.
EBITDA margin target of 13.5-14% for FY27
Targeting EBITDA margins between 13.5% and 14% for FY27, assuming stable crude prices; without war, target was 14-14.5%.
Capex plan of ₹300-400 crore over 2-3 years
Planned capex for brownfield expansions and formulation capacity, including oncology, over the next 2-3 years.